MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fanelli, F.
Right arrow Articles by Chini, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fanelli, F.
Right arrow Articles by Chini, B.

Vol. 56, Issue 1, 214-225, July 1999

Activation Mechanism of Human Oxytocin Receptor: A Combined Study of Experimental and Computer-Simulated Mutagenesis

Francesca Fanelli, Pascaline Barbier, Deborah Zanchetta, Pier G. de Benedetti, and Bice Chini

Department of Chemistry, University of Modena, Modena, Italy (F.F., P.G.DeB.); Consiglio Nazionale delle Richerche Cellular and Molecular Pharmacology Center, Department of Pharmacology, University of Milan, Milan, Italy (P.B., D.Z., B.C.)

The aim of this study was to investigate the molecular changes associated with the transition of the human oxytocin receptor from its inactive to its active states. Mutation of the conserved arginine of the glutamate/aspartate-arginine-tyrosine motif located in the second intracellular domain gave rise to the first known constitutively active oxytocin receptor (R137A), whereas mutation of the aspartic acid located in the second transmembrane domain led to an inactive receptor (D85A). The structural features of the constitutively active and inactive receptor mutants were compared with those of the wild type in its free and agonist-bound states. The results suggest that, although differently triggered, the activation process induced by the agonist and the activating mutation are characterized by the opening of a solvent exposed site formed by the 2nd intracellular loop, the cytosolic extension of helix 5, and the 3rd intracellular loop; on the contrary, the D85A mutation prevents oxytocin from triggering the opening of a cytosolic site. On the basis of these findings, we hypothesize that this cytosolic crevice plays an important role in G protein recognition. Finally, comparative analysis of the free- and agonist-bound forms of the wild-type oxytocin receptor and alpha 1B adrenergic receptor suggests that the highly conserved polar amino acids and the seven helices play similar mechanistic roles in the different G protein-coupled receptors.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Zhong, B. Parish, D. A. Murtazina, C.-Y. Ku, and B. M. Sanborn
Amino acids in the COOH-terminal region of the oxytocin receptor third intracellular domain are important for receptor function
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E977 - E984.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. R. Hawtin
Charged Residues of the Conserved DRY Triplet of the Vasopressin V1a Receptor Provide Molecular Determinants for Cell Surface Delivery and Internalization
Mol. Pharmacol., October 1, 2005; 68(4): 1172 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. A. Flanagan
A GPCR That Is Not "DRY"
Mol. Pharmacol., July 1, 2005; 68(1): 1 - 3.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. M. Rosenkilde, T. N. Kledal, and T. W. Schwartz
High Constitutive Activity of a Virus-Encoded Seven Transmembrane Receptor in the Absence of the Conserved DRY Motif (Asp-Arg-Tyr) in Transmembrane Helix 3
Mol. Pharmacol., July 1, 2005; 68(1): 11 - 19.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Li, N. M. Nowak, S.-K. Kim, K. A. Jacobson, A. Bagheri, C. Schmidt, and J. Wess
Random Mutagenesis of the M3 Muscarinic Acetylcholine Receptor Expressed in Yeast: IDENTIFICATION OF SECOND-SITE MUTATIONS THAT RESTORE FUNCTION TO A COUPLING-DEFICIENT MUTANT M3 RECEPTOR
J. Biol. Chem., February 18, 2005; 280(7): 5664 - 5675.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
A Levoye, B Mouillac, G Riviere, D Vieau, M Salzet, and C Breton
Cloning, expression and pharmacological characterization of a vasopressin-related receptor in an annelid, the leech Theromyzon tessulatum
J. Endocrinol., January 1, 2005; 184(1): 277 - 289.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Madabushi, A. K. Gross, A. Philippi, E. C. Meng, T. G. Wensel, and O. Lichtarge
Evolutionary Trace of G Protein-coupled Receptors Reveals Clusters of Residues That Determine Global and Class-specific Functions
J. Biol. Chem., February 27, 2004; 279(9): 8126 - 8132.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Yang, W. Wang, M. Zhong, A. Philippi, O. Lichtarge, and B. M. Sanborn
Lysine 270 in the Third Intracellular Domain of the Oxytocin Receptor is an Important Determinant for G{alpha}q Coupling Specificity
Mol. Endocrinol., April 1, 2002; 16(4): 814 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Bussolati, M. Chinol, B. Chini, A. Nacca, P. Cassoni, and G. Paganelli
111In-labeled 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid-Lys8-Vasotocin: A New Powerful Radioligand for Oxytocin Receptor-expressing Tumors
Cancer Res., June 1, 2001; 61(11): 4393 - 4397.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
G. Gimpl and F. Fahrenholz
The Oxytocin Receptor System: Structure, Function, and Regulation
Physiol Rev, April 1, 2001; 81(2): 629 - 683.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Kitanovic, T. Yuen, C. A. Flanagan, B. J. Ebersole, and S. C. Sealfon
Insertional Mutagenesis of the Arginine Cage Domain of the Gonadotropin-Releasing Hormone Receptor
Mol. Endocrinol., March 1, 2001; 15(3): 390 - 397.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
M. C. Gershengorn and R. Osman
Minireview: Insights into G Protein-Coupled Receptor Function Using Molecular Models
Endocrinology, January 1, 2001; 142(1): 2 - 10.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
E. ALBERTAZZI, D. ZANCHETTA, P. BARBIER, S. FARANDA, A. FRATTINI, P. VEZZONI, M. PROCACCIO, A. BETTINELLI, F. GUZZI, M. PARENTI, et al.
Nephrogenic Diabetes Insipidus: Functional Analysis of New AVPR2Mutations Identified in Italian Families
J. Am. Soc. Nephrol., June 1, 2000; 11(6): 1033 - 1043.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
A. Scheer, T. Costa, F. Fanelli, P. G. De Benedetti, S. Mhaouty-Kodja, L. Abuin, M. Nenniger-Tosato, and S. Cotecchia
Mutational Analysis of the Highly Conserved Arginine within the Glu/Asp-Arg-Tyr Motif of the alpha 1b-Adrenergic Receptor: Effects on Receptor Isomerization and Activation
Mol. Pharmacol., February 1, 2000; 57(2): 219 - 231.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
H. H. Ho, N. Ganeshalingam, A. Rosenhouse-Dantsker, R. Osman, and M. C. Gershengorn
Charged Residues at the Intracellular Boundary of Transmembrane Helices 2 and 3 Independently Affect Constitutive Activity of Kaposi's Sarcoma-associated Herpesvirus G Protein-coupled Receptor
J. Biol. Chem., January 5, 2001; 276(2): 1376 - 1382.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics